Dupilumab in the Treatment of Pediatric Alopecia Areata

This trial tests dupilumab — a biologic drug already approved for eczema and asthma that blocks the immune signaling molecules IL-4 and IL-13 — for treating severe alopecia areata (AA) in children. AA is an autoimmune disease where the immune system attacks hair follicles, causing patchy or total hair loss. It can be devastating for children's psychological development and self-image, and current treatments are often inadequate or cause significant side effects. The trial builds on adult studies showing dupilumab can restore hair growth in patients who also have atopic (allergic) backgrounds. Children aged 6 to 17 with at least six months of moderate to severe alopecia areata (50% or more scalp hair loss) who have elevated IgE levels or a personal or family history of atopic conditions (eczema, asthma, allergies) are eligible. Children who are pregnant, breastfeeding, have indeterminate hair loss causes, have had no hair regrowth for 7 or more years, have severe uncontrolled asthma, active infections, immunodeficiency, or serious chronic disease are excluded. Participants receive dupilumab injections and are assessed for scalp hair regrowth over the study period. This research is meaningful because alopecia areata can cause profound psychological harm in children at a critical stage of identity development, and a safe and effective targeted treatment would fill a significant unmet need in pediatric dermatology.